J.P. Morgan Notebook, Jan. 13: Drug Costs, Gilead, Valeant, Allergan/Actavis, Bristol

14 Jan 2015

• By Emily Hayes and Jessica Merrill

Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the 2015 J.P. Morgan Healthcare Conference in San Francisco. Pricing talk dominates day two, and companies weigh in on the fallout from failed M&A.

J.P. Morgan Notebook, Jan. 13: Drug Costs, Gilead, Valeant, Allergan/Actavis, Bristol

More from Clinical Trials

More from R&D